End-to-End Cell Therapy Automation: An Immunotherapy Case Study

Consider automation early in the rollout of clinical translation and scale up of clinical-trial protocols.
Sep 15, 2017
Volume 2017 eBook, Issue 2, pg 10–18

As anticipation builds about accelerated clinical adoption of advanced cell therapies, more attention is turning to the underlying manufacturing strategies that will allow these therapies to benefit patients worldwide. While cell therapies hold great promise clinically, high manufacturing costs relative to reimbursement present a formidable roadblock to commercialization. Therefore, the need for cost effectiveness, process efficiency, and product consistency is driving efforts for automation in numerous cell therapy fields and particularly for T-cell immunotherapies. 

Read this article from BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.

View other articles in BioPharm International’s 2017 Development Strategies for Emerging Therapies eBook.

Article Details

BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 10–18

Citation

When referring to this article, please cite it as J. Morrissey, N. Trainor, and Y. Shi, "End-to-End Cell Therapy Automation: An Immunotherapy Case Study," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).

native1_300x100
lorem ipsum